Patent Granted for MoAbs Used in Neoprobe's RIGScan Products
DUBLIN, Ohio--Neoprobe Corporation has announced that a patent granted to Jeffrey Schlom, PhD, of the National Cancer Institute, and David Colcher, PhD, of the University of Nebraska Medical Center, covers claims to composition of matter for a large group of second-generation monoclonal antibodies that target the tumor-associated antigen TAG-72.
DUBLIN, Ohio--Neoprobe Corporation has announced that a patentgranted to Jeffrey Schlom, PhD, of the National Cancer Institute,and David Colcher, PhD, of the University of Nebraska MedicalCenter, covers claims to composition of matter for a large groupof second-generation monoclonal antibodies that target the tumor-associatedantigen TAG-72.
Neoprobe holds an exclusive global license for use of these antibodieswith its RIGS technology for surgical detection and treatmentof cancer. The antibodies named in the patent include CC49, acomponent of Neo-probe's first commercial product, RIGScan CR49,currently under investigation for colorectal cancer.
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
